Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IDEC 132 oral

Drug Profile

IDEC 132 oral

Alternative Names: 9-AC PEG-1000 - IDEC; 9-aminocamptothecin PEG-1000 - IDEC; IDEC 132 colloidal dispersion; IDEC 132 PEG-1000; PEG-1000 - IDEC

Latest Information Update: 10 Aug 1999

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IDEC Pharmaceuticals
  • Class Alkaloids; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 10 Aug 1999 Discontinued-II for Cancer in USA (PO)
  • 09 Aug 1999 Clinical studies have been added to the pharmacokinetics section
  • 28 Jul 1999 Phase-I clinical trials for Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top